Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. (2022)

First Author: Pattni K


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s12879-022-07239-z

PubMed Identifier: 35307024

Publication URI: http://europepmc.org/abstract/MED/35307024

Type: Journal Article/Review

Volume: 22

Parent Publication: BMC infectious diseases

Issue: 1

ISSN: 1471-2334